Overall rank by patents
#42,009
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Norlase Aps
USPTO PatentsView assignee record - 6 granted patents across 8 technology areas, active 2021–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
6
Total patents granted
8
CPC technology areas
22.7
Avg claims per patent
-
5-year filing velocity
The verdict
Norlase holds 6 US patents across 8 technology areas, rank #42,009 of 50,000 tracked assignees.
- #42,009
- of 50,000 US assignees by volume
- Top 28%
- by Innovation Score (43.7/100)
- 22.7
- avg claims per patent
Portfolio overview
Norlase Aps has been granted 6 US utility patents between 2021 and 2025, placing Norlase Aps at rank #42,009 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.7 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a Foreign Corporation, Norlase Aps is one of the more focused assignees in the PatentsView dataset. By volume, Norlase sits between Nittany Solutions Group, Llc (6 patents, rank #42,005) and North American Manufacturing Enterprises (6 patents, rank #42,013) - the closest US assignees by grant volume. The composite Innovation Score of 43.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2021 through 2025, with 6 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Norlase Aps's 22.7 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Norlase Aps against peers pursuing similar technology classes.
Who files at Norlase's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Nittany Solutions…
Nittany Solutions Group, LLC
6 patents
- Noble Research In…
Noble Research Institute, LLC
6 patents
- Norbar Torque Too…
Norbar Torque Tools Limited
6 patents
- Norcros Group (Ho…
Norcros Group (Holdings) Limited
6 patents
- Normark Innovatio…
Normark Innovations, Inc.
6 patents
- Noroo IC
Noroo IC Co., Ltd.
6 patents
- Nortek Global HVAC
Nortek Global HVAC, LLC
6 patents
- North American Ma…
North American Manufacturing Enterprises
6 patents
- Norlase Aps ◀
Norlase ApS
6 patents
What this shows Norlase holds 6 patents at rank #42,009, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Norlase
By rank, the assignees closest to #42,009 in granted patent volume.
- Nittany Solutions Group, Llc #42,005 · 6 patents
- Noble Research Institute, Llc #42,006 · 6 patents
- Norbar Torque Tools Limited #42,007 · 6 patents
- Norcros Group (holdings) Limited #42,008 · 6 patents
- Normark Innovations, Inc. #42,010 · 6 patents
- Noroo IC Co., Ltd. #42,011 · 6 patents
- Nortek Global HVAC, Llc #42,012 · 6 patents
- North American Manufacturing Enterprises #42,013 · 6 patents
Leaders in A61F (Filters Implantable INTO Blood Vessels)
Other assignees with the most granted patents in Norlase's primary technology class.
- The Procter & Gamble Company 1,426 in class
- Boston Scientific Scimed, Inc. 1,101 in class
- Edwards Lifesciences Corporation 1,101 in class
- Depuy Synthes Products, Inc. 851 in class
- Globus Medical, Inc. 752 in class
- COOK Medical Technologies Llc 700 in class
- Smith & Nephew, Inc. 541 in class
- Covidien Lp 528 in class
Norlase's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
44 Top 28% higher than 72% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 1 | 16.7% |
| 2023 | 1 | 16.7% |
| 2024 | 1 | 16.7% |
| 2025 | 3 | 50.0% |
Which technologies does Norlase Aps patent most?
Top 8 of 8 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Frequently Asked Questions
How many patents does Norlase Aps hold?
Norlase Aps holds 6 US granted patents filed between 2021 and 2025, spanning 8 technology areas.
What is Norlase Aps's Innovation Score?
Norlase Aps has an Innovation Score of 43.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Norlase Aps focus on?
Norlase Aps's top technology area is A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS) with 6 patents. The company has filed patents in 8 CPC subclasses total.
Is Norlase Aps's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Norlase Aps.
What does claim depth mean for Norlase Aps's patents?
Norlase Aps's patents average 22.7 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Norlase Aps patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Norlase's 6 grants land it in the top 28% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Norlase ranks #42,009 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61F - see who else leads that technology area. A61F leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.